This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Battistello E., Katanayeva N., Dheilly E., Tavernari D., Donaldson M.C., Bonsignore, L., Thome M., Christie A.L., Murakami M.A., Michielin O., Ciriello, G., Zoete V., Oricchio E.: Pan-SRC kinase inhibition blocks B-cell receptor oncogenic signaling in non-Hodgkin lymphoma. Blood 2018, 131, 2345–2356, doi: 10.1182/blood-2017-10-809210.BattistelloE.KatanayevaN.DheillyE.TavernariD.DonaldsonM.C.BonsignoreL.ThomeM.ChristieA.L.MurakamiM.A.MichielinO.CirielloG.ZoeteV.OricchioE.Pan-SRC kinase inhibition blocks B-cell receptor oncogenic signaling in non-Hodgkin lymphoma20181312345235610.1182/blood-2017-10-809210596937729567799Open DOISearch in Google Scholar
Bavcar S., Argyle D.J.: Receptor tyrosine kinase inhibitors: molecularly targeted drugs for veterinary cancer therapy. Vet Comp Oncol 2012, 10, 163–173, doi: 10.1111/j.1476-5829.2012.00342.x.BavcarS.ArgyleD.J.Receptor tyrosine kinase inhibitors: molecularly targeted drugs for veterinary cancer therapy20121016317310.1111/j.1476-5829.2012.00342.x22882485Open DOISearch in Google Scholar
Chang C.Y., Chiou P.P., Chen W.J., Li Y.H., Yiu J.C., Cheng Y.H., Chen S.D., Lin C.T., Lai Y.S.: Assessment of the tumorigenesis and drug susceptibility of three new canine mammary tumor cell lines. Res Vet Sci 2010, 88, 285–293, doi: 10.1016/j.rvsc.2009.08.006.ChangC.Y.ChiouP.P.ChenW.J.LiY.H.YiuJ.C.ChengY.H.ChenS.D.LinC.T.LaiY.S.Assessment of the tumorigenesis and drug susceptibility of three new canine mammary tumor cell lines20108828529310.1016/j.rvsc.2009.08.00619748110Open DOISearch in Google Scholar
Ciardiello F., Tortora G.: A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001, 7, 2958–2970.CiardielloF.TortoraG.A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor2001729582970Search in Google Scholar
Dubreuil P., Letard S., Ciufolini M., Gros L., Humbert M., Castéran N., Borge L., Hajem B., Lermet A., Sippl W., Voisset E., Arock M., Auclair C., Leventhal P.S., Mansfield C.D., Moussy A., Hermine O.: Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. PloS One 2009, 4, e7258, doi: 10.1371/journal.pone.0007258.DubreuilP.LetardS.CiufoliniM.GrosL.HumbertM.CastéranN.BorgeL.HajemB.LermetA.SipplW.VoissetE.ArockM.AuclairC.LeventhalP.S.MansfieldC.D.MoussyA.HermineO.Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT20094e725810.1371/journal.pone.0007258274628119789626Open DOISearch in Google Scholar
Fahey C.E., Milner R.J., Kow K., Bacon N.J., Salute M.E.: Apoptotic effects of the tyrosine kinase inhibitor, masitinib mesylate, on canine osteosarcoma cells. Anti-Cancer Drugs 2013, 24, 519–526, doi: 10.1097/CAD.0b013e32836002ba.FaheyC.E.MilnerR.J.KowK.BaconN.J.SaluteM.E.Apoptotic effects of the tyrosine kinase inhibitor, masitinib mesylate, on canine osteosarcoma cells20132451952610.1097/CAD.0b013e32836002ba23466652Open DOISearch in Google Scholar
Hahn K.A., Oglivie G., Rusk T., Devauchelle P., Leblanc A., Legendre A., Powers B., Leventhal P.S., Kinet J.P., Palmerini F., Dubreuil P., Moussy A., Hermine O.: Masitinib is safe and effective for the treatment of canine mast cell tumors. J Vet Intern Med 2008, 22, 1301–1309, doi: 10.1111/j.1939-1676.2008.0190.x.HahnK.A.OglivieG.RuskT.DevauchelleP.LeblancA.LegendreA.PowersB.LeventhalP.S.KinetJ.P.PalmeriniF.DubreuilP.MoussyA.HermineO.Masitinib is safe and effective for the treatment of canine mast cell tumors2008221301130910.1111/j.1939-1676.2008.0190.x18823406Open DOISearch in Google Scholar
Holtermann N., Kiupel M., Kessler M., Teske E., Betz D., Hirschberger J.: Masitinib monotherapy in canine epitheliotropic lymphoma. Vet Comp Oncol 2016, 14, 127–135, doi: 10.1111/ vco.12157.HoltermannN.KiupelM.KesslerM.TeskeE.BetzD.HirschbergerJ.Masitinib monotherapy in canine epitheliotropic lymphoma20161412713510.1111/vco.1215726364581Open DOISearch in Google Scholar
Karayannopoulou M., Lafioniatis S.: Recent advances on canine mammary cancer chemotherapy: A review of studies from 2000 to date. Revue Méd Vét 2016, 167, 192–200.KarayannopoulouM.LafioniatisS.Recent advances on canine mammary cancer chemotherapy: A review of studies from 2000 to date2016167192200Search in Google Scholar
Kaszak I., Ruszczak A., Kanafa S., Kacprzak K., Król M., Jurka P.: Current biomarkers of canine mammary tumors. Acta Vet Scand 2018, 60, 66, doi: 10.1186/s13028-018-0417-1.KaszakI.RuszczakA.KanafaS.KacprzakK.KrólM.JurkaP.Current biomarkers of canine mammary tumors2018606610.1186/s13028-018-0417-1620670430373614Open DOISearch in Google Scholar
Kato Y., Asano K., Mogi T., Kutara K., Teshima K., Edamura K., Tsumagari S., Hasegawa A., Tanaka S.: Clinical significance of circulating vascular endothelial growth factor in dogs with mammary gland tumors. J Vet Med Sci 2007, 69, 77–80, doi: 10.1292/jvms.69.77.KatoY.AsanoK.MogiT.KutaraK.TeshimaK.EdamuraK.TsumagariS.HasegawaA.TanakaS.Clinical significance of circulating vascular endothelial growth factor in dogs with mammary gland tumors200769778010.1292/jvms.69.7717283406Open DOISearch in Google Scholar
Koltai Z., Szabó B., Jakus J., Vajdovich P.: Tyrosine kinase expression analyses in canine mammary gland tumours – A pilot study. Acta Vet Hung 2018, 66, 294–308, doi: 10.1556/004.2018.027.KoltaiZ.SzabóB.JakusJ.VajdovichP.Tyrosine kinase expression analyses in canine mammary gland tumours – A pilot study20186629430810.1556/004.2018.02729958529Open DOISearch in Google Scholar
Kubo K., Matsuyama S., Katayama K., Tsutsumi C., Yonezawa K., Shimada T., Kotani T., Sakuma S., Ohashi F., Takamori Y.: Frequent expression of the c-kit proto-oncogene in canine malignant mammary tumor. J Vet Med Sci 1998, 60, 1335–1340, doi: 10.1292/jvms.60.1335.KuboK.MatsuyamaS.KatayamaK.TsutsumiC.YonezawaK.ShimadaT.KotaniT.SakumaS.OhashiF.TakamoriY.Frequent expression of the c-kit proto-oncogene in canine malignant mammary tumor1998601335134010.1292/jvms.60.13359879535Open DOISearch in Google Scholar
Lawrence J., Saba C., Gogal Jr R., Lamberth O., Vandenplas M.L., Hurley D.J., Dubreuil P., Hermine O., Dobbin K., Turek M.: Masitinib demonstrates anti‐proliferative and pro‐apoptotic activity in primary and metastatic feline injection‐site sarcoma cells. Vet Comp Oncol 2012, 10, 143–154, doi: 10.1111/j.1476-5829.2011.00291.x.LawrenceJ.SabaC.GogalJr R.LamberthO.VandenplasM.L.HurleyD.J.DubreuilP.HermineO.DobbinK.TurekM.Masitinib demonstrates anti‐proliferative and pro‐apoptotic activity in primary and metastatic feline injection‐site sarcoma cells20121014315410.1111/j.1476-5829.2011.00291.x22236016Open DOISearch in Google Scholar
Lyles S.E., Milner R.J., Kow K., Salute M.E.: In vitro effects of the tyrosine kinase inhibitor, masitinib mesylate, on canine hemangiosarcoma cell lines. Vet Comp Oncol 2012, 10, 223–235, doi: 10.1111/j.1476-5829.2012.00335.x.LylesS.E.MilnerR.J.KowK.SaluteM.E.In vitro effects of the tyrosine kinase inhibitor, masitinib mesylate, on canine hemangiosarcoma cell lines20121022323510.1111/j.1476-5829.2012.00335.x22594682Open DOISearch in Google Scholar
Marech I., Patruno R., Zizzo N., Gadaleta C., Introna M., Zito A.F., Gadaleta C.D., Ranieri G.: Masitinib (AB1010), from canine tumor model to human clinical development: where we are? Crit Rev Oncol Hematol 2014, 91, 98–111, doi: 10.1016/j.critrevonc.2013.12.011.MarechI.PatrunoR.ZizzoN.GadaletaC.IntronaM.ZitoA.F.GadaletaC.D.RanieriG.Masitinib (AB1010), from canine tumor model to human clinical development: where we are?2014919811110.1016/j.critrevonc.2013.12.01124405856Open DOISearch in Google Scholar
Michishita M., Ohtsuka A., Nakahira R., Tajima T., Nakagawa T., Sasaki N., Arai T., Takahashi K.: Anti-tumor effect of bevacizumab on a xenograft model of feline mammary carcinoma. J Vet Med Sci 2016, 78, 685–694, doi: 10.1292/jvms.15-0550.MichishitaM.OhtsukaA.NakahiraR.TajimaT.NakagawaT.SasakiN.AraiT.TakahashiK.Anti-tumor effect of bevacizumab on a xenograft model of feline mammary carcinoma20167868569410.1292/jvms.15-0550487386226616000Open DOISearch in Google Scholar
Milovancev M., Helfand S.C., Marley K., Goodall C.P., Löhr C.V., Bracha S.: Antiproliferative effects of masitinib and imatinib against canine oral fibrosarcoma in vitro. BMC Vet Res 2016, 12, 85, doi: 10.1186/s12917-016-0712-x.MilovancevM.HelfandS.C.MarleyK.GoodallC.P.LöhrC.V.BrachaS.Antiproliferative effects of masitinib and imatinib against canine oral fibrosarcoma in vitro2016128510.1186/s12917-016-0712-x489327927259510Open DOISearch in Google Scholar
Pena L.L., Nieto A.I., Pérez-Alenza D., Cuesta P., Castano M.: Immunohistochemical detection of Ki-67 and PCNA in canine mammary tumors: relationship to clinical and pathologic variables. J Vet Diagn Invest 1998, 10, 237–246, doi: 10.1177/104063879801000303.PenaL.L.NietoA.I.Pérez-AlenzaD.CuestaP.CastanoM.Immunohistochemical detection of Ki-67 and PCNA in canine mammary tumors: relationship to clinical and pathologic variables19981023724610.1177/1040638798010003039683072Open DOISearch in Google Scholar
Queiroga F.L., Raposo T., Carvalho M.I., Prada J., Pires I.: Canine mammary tumours as a model to study human breast cancer: most recent findings. In Vivo 2011, 25, 455–465.QueirogaF.L.RaposoT.CarvalhoM.I.PradaJ.PiresI.Canine mammary tumours as a model to study human breast cancer: most recent findings201125455465Search in Google Scholar
Ranieri G., Gadaleta C.D., Patruno R., Zizzo N., Daidone M.G., Hansson M.G., Paradiso A., Ribatti D.: A model of study for human cancer: Spontaneous occurring tumors in dogs. Biological features and translation for new anticancer therapies. Crit Rev Oncol Hematol 2013, 88, 187–197, doi: 10.1016/j.critrevonc.2013.03.005.RanieriG.GadaletaC.D.PatrunoR.ZizzoN.DaidoneM.G.HanssonM.G.ParadisoA.RibattiD.A model of study for human cancer: Spontaneous occurring tumors in dogs20138818719710.1016/j.critrevonc.2013.03.00523561333Open DOISearch in Google Scholar
Restucci B., Papparella S., Maiolino P., De Vico G.: Expression of vascular endothelial growth factor in canine mammary tumors. Vet Pathol 2002, 39, 488–493, doi: 10.1354/vp.39-4-488.RestucciB.PapparellaS.MaiolinoP.De VicoG.Expression of vascular endothelial growth factor in canine mammary tumors20023948849310.1354/vp.39-4-48812126152Open DOISearch in Google Scholar
Sandström M., Johansson M., Andersson U., Bergh A., Bergenheim A.T., Henriksson R.: The tyrosine kinase inhibitor ZD6474 inhibits tumour growth in an intracerebral rat glioma model. Br J Cancer 2004, 91, 1174–1180, doi: 10.1038/sj.bjc.6602108.SandströmM.JohanssonM.AnderssonU.BerghA.BergenheimA.T.HenrikssonR.The tyrosine kinase inhibitor ZD6474 inhibits tumour growth in an intracerebral rat glioma model2004911174118010.1038/sj.bjc.6602108274768815305185Open DOISearch in Google Scholar
Scholzen T., Gerdes J.: The Ki‐67 protein: from the known and the unknown. J Cell Physiol 2000, 182, 311–322, doi: 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9.ScholzenT.GerdesJ.The Ki‐67 protein: from the known and the unknown200018231132210.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9Open DOISearch in Google Scholar
Stabile L.P., Lyker J.S., Gubish C.T., Zhang W., Grandis J.R., Siegfried J.M.: Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non–small cell lung cancer shows enhanced antiproliferative effects. Cancer Res 2005, 65, 1459–1470, doi: 10.1158/0008-5472.CAN-04-1872.StabileL.P.LykerJ.S.GubishC.T.ZhangW.GrandisJ.R.SiegfriedJ.M.Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non–small cell lung cancer shows enhanced antiproliferative effects2005651459147010.1158/0008-5472.CAN-04-1872Open DOISearch in Google Scholar
Thamm D.H., Rose B., Kow K., Humbert M., Mansfield C.D., Moussy A., Hermine O., Dubreuil P.: Masitinib as a chemosensitizer of canine tumor cell lines: a proof of concept study. Vet J 2012, 191, 131–134, doi: 10.1016/j.tvjl.2011.01.001.ThammD.H.RoseB.KowK.HumbertM.MansfieldC.D.MoussyA.HermineO.DubreuilP.Masitinib as a chemosensitizer of canine tumor cell lines: a proof of concept study201219113113410.1016/j.tvjl.2011.01.001Open DOISearch in Google Scholar
Wilhelm S.M., Adnane L., Newell P., Villanueva A., Llovet J.M., Lynch M.: Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008, 7, 3129–3140, doi: 10.1158/1535-7163.MCT-08-0013.WilhelmS.M.AdnaneL.NewellP.VillanuevaA.LlovetJ.M.LynchM.Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling200873129314010.1158/1535-7163.MCT-08-0013Open DOISearch in Google Scholar
Wolfesberger B., Tonar Z., Gerner W., Skalicky M., Heiduschka G., Egerbacher M., Thalhammer J.G., Walter I.: The tyrosine kinase inhibitor sorafenib decreases cell number and induces apoptosis in a canine osteosarcoma cell line. Res Vet Sci 2010, 88, 94–100, doi: 10.1016/j.rvsc.2009.06.009.WolfesbergerB.TonarZ.GernerW.SkalickyM.HeiduschkaG.EgerbacherM.ThalhammerJ.G.WalterI.The tyrosine kinase inhibitor sorafenib decreases cell number and induces apoptosis in a canine osteosarcoma cell line2010889410010.1016/j.rvsc.2009.06.009Open DOISearch in Google Scholar
Xiao X., Wu J., Zhu X., Zhao P., Zhou J., Liu Q.Q., Zheng L., Zeng M., Liu R., Huang W.: Induction of cell cycle arrest and apoptosis in human nasopharyngeal carcinoma cells by ZD6474, an inhibitor of VEGFR tyrosine kinase with additional activity against EGFR tyrosine kinase. Int J Cancer 2007, 121, 2095–2104, doi: 10.1002/ijc.22955.XiaoX.WuJ.ZhuX.ZhaoP.ZhouJ.LiuQ.Q.ZhengL.ZengM.LiuR.HuangW.Induction of cell cycle arrest and apoptosis in human nasopharyngeal carcinoma cells by ZD6474, an inhibitor of VEGFR tyrosine kinase with additional activity against EGFR tyrosine kinase20071212095210410.1002/ijc.22955Open DOISearch in Google Scholar
Zhou X., Zheng M., Chen F., Zhu Y., Yong W., Lin H., Sun Y., Han X.: Gefitinib inhibits the proliferation of pancreatic cancer cells via cell cycle arrest. Anat Rec (Hoboken) 2009, 292, 1122–1127, doi: 10.1002/ar.20938.ZhouX.ZhengM.ChenF.ZhuY.YongW.LinH.SunY.HanX.Gefitinib inhibits the proliferation of pancreatic cancer cells via cell cycle arrest20092921122112710.1002/ar.20938Open DOISearch in Google Scholar